Everything below concerns Ion-pairing chromatography. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
Stability studies indicate that NMN is sensitive to heat, light, and pH extremes. In aqueous solution, hydrolysis can cleave the phosphate linkage or convert NMN to related nicotinamide derivatives, with degradation accelerating at elevated temperatures and alkaline conditions. Solid material is generally more stable when kept dry and cold, and research-grade supplies are often stored at minus twenty degrees Celsius or lower, protected from light and moisture. Repeated freeze-thaw cycles of solutions can promote degradation, so aliquoting is a common laboratory practice. The exact shelf life depends on purity, counterion, packaging, and storage history.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C11H15N2O8P | Neutral form; often supplied as a salt or hydrate. |
| Molecular weight | 334.22 g/mol | Calculated for C11H15N2O8P. |
| Appearance | White to off-white powder | Color can vary with purity and hydration. |
| Solubility | Soluble in water | Aqueous solutions are acidic and stability depends on pH and temperature. |
| Typical storage | −20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw cycles. |
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Quality control for NMN materials typically includes identity, assay, purity, and impurity profiling. Tests may cover residual solvents, heavy metals, microbial limits, and water content, depending on the intended use and local rules. Impurity profiles can include related substances such as nicotinamide, nicotinamide riboside, and NAD+, which may form during synthesis or storage. Because commercial NMN can be offered as different salts or hydrate forms, a certificate of analysis should state the form and the analytical methods used. Independent verification is relevant because supplement markets vary in testing requirements and enforcement.
Laboratory identification of NMN usually relies on chromatographic separation coupled with ultraviolet or mass spectrometric detection. High-performance liquid chromatography with UV absorbance can quantify the compound against a reference standard, while liquid chromatography-tandem mass spectrometry offers lower detection limits and better specificity in complex matrices. Nuclear magnetic resonance spectroscopy can confirm structural identity and isomeric form. Ion chromatography or capillary electrophoresis may be used to identify counterions such as sodium. Method validation includes accuracy, precision, linearity, and limits of detection.
== Entrepreneurial Activities == In 2000 Gerngross co-founded Glycofi, Inc. and served as the company's Chief Scientific Officer until its acquisition by Merck & Co. in the spring of 2006. In the fall of 2006 Dr. Gerngross joined SV Life Sciences as a venture partner where he advises on investments in the bio-therapeutics area. SV Life Sciences manages five investment funds with an aggregate capital of about $1.6 billion. In 2007 Dr. Gerngross co-founded Adimab LLC. with Prof. Dane Wittrup at MIT and Errik Anderson to develop a novel platform for the discovery of human antibodies in yeast. Gerngross stepped down from heading Adimab in February 2023, and was replaced by lawyer Philip Chase. To date the company has raised five rounds of venture financing from Polaris Ventures, SV Life Sciences, Google Ventures, OrbiMed Advisors, and Borealis Ventures and employs about 70 people in Lebanon, New Hampshire. In 2020, Gerngross cofounded Adagio as a spinout of Adimab which was developing a treatment for COVID-19. In Feb. 2022, Tillman Gerngross resigned as head of the company amid concerns about the efficacy of the drug. The company changed its name to Invivyd and broadened its focus in September 2022. There is currently a pending case of fraud against Tillman related to Adagio in Massachusetts, filed January 2023. In January 2022, Gerngross introduced a new company, Amagma, which also focused on developing antibodies. Amagma was folded in 2023, and the status of its assets are unknown.
Initially, Zverev had difficulty adjusting to this training style on the court, saying, "I had no idea what was going on in my body", and needed to adapt his shot technique as he became more muscular. Eventually, he improved on the court. Green remarked, "He started to become less wobbly. He started to absorb the power, so when someone hit hard he could hit the ball back and everything locked into place."
The primary form of fixed inorganic carbon is carbon dioxide (CO2). It is estimated that approximately 250 billion tons of carbon dioxide are converted by photosynthesis annually, nearly one half in the oceans and a bit more in terrestrial environments. The majority of the fixation in terrestrial environments occurs in the tropics. The gross amount of carbon dioxide fixed is much larger since approximately 40% is consumed by respiration following photosynthesis. Historically, it is estimated that approximately 2×1011 billion tons of carbon has been fixed since the origin of life.
=== Pharmacokinetics === Variations in ADME, i.e. an individual's efficiency in absorbing, tissue-distributing, metabolizing, or excreting a drug, have been found to occur in various severe cutaneous adverse reactions (SCARS) as well as other types of adverse drug reactions. These variations influence the levels and duration of a drug or its metabolite in tissues and thereby impact the drug's or metabolite's ability to evoke these reactions. For example, CYP2C9 is an important drug-metabolizing cytochrome P450; it metabolizes and thereby inactivates phenytoin. Taiwanese, Japanese, and Malaysian individuals expressing the CYP2C9*3 variant of CYP2C9, which has reduced metabolic activity compared to the wild type (i.e. CYP2c9*1) cytochrome, have increased blood levels of phenytoin and a high incidence of SJS (as well as SJS/TEN and TEN) when taking the drug. In addition to abnormalities in drug-metabolizing enzymes, dysfunctions of the kidney, liver, or GI tract which increase a SCARs-inducing drug or metabolite levels are suggested to promote SCARs responses. These ADME abnormalities, it is also suggested, may interact with particular HLA proteins and T cell receptors to promote a SCARs disorder.
Sources: en.wikipedia.org
Gearbox Software, L.L.C. is an American video game development company based in Frisco, Texas. It was established as a limited liability company in February 1999 by five developers formerly of Rebel Boat Rocker. Randy Pitchford, one of the founders, serves as president and chief executive officer. Gearbox initially created expansions for the Valve game Half-Life, then ported that game and others to console platforms. In 2005, Gearbox launched its first independent set of games, Brothers in Arms, on console and mobile devices. It became its flagship franchise and spun off a comic book series, television documentary, books, and action figures. Their second original game series, Borderlands, commenced in 2009, and by 2015 had sold over 26 million copies. The company also owns the intellectual property of Duke Nukem and Homeworld. Gearbox expanded into publishing with the creation of Gearbox Publishing in 2015. A parent company, The Gearbox Entertainment Company, was established for Gearbox Software and Gearbox Publishing in 2019. Gearbox Entertainment was acquired by the Embracer Group in April 2021, becoming its seventh major label. A third division, Gearbox Studios, focusing on television and film productions, was established in October 2021. Due to major restructuring following a failed investment, Embracer announced plans to divest Gearbox to Take-Two Interactive, who had previously published several of Gearbox's games under its 2K label, in March 2024. Take-Two Interactive closed the Gearbox Software acquisition on June 12, 2024.
=== America, Iran, and Under Milk Wood, 1950–1953 === American poet John Brinnin invited Thomas to New York, where in February 1950 they embarked on a lucrative three-month tour of arts centres and campuses. The tour, which began in front of an audience of a thousand at the Kaufmann Auditorium of the Poetry Centre in New York, took in about 40 venues. During the tour, Thomas was invited to many parties and functions and on several occasions became drunk—going out of his way to shock people—and was a difficult guest. Thomas drank before some of his readings, though it is argued he may have pretended to be more affected by it than he actually was. The writer Elizabeth Hardwick recalled how intoxicating a performer he was and how the tension would build before a performance: "Would he arrive only to break down on the stage? Would some dismaying scene take place at the faculty party? Would he be offensive, violent, obscene?" Caitlin said in her memoir, "Nobody ever needed encouragement less, and he was drowned in it." On returning to Britain, Thomas began work on two further poems, "In the white giant's thigh", which he read on the Third Programme in September 1950, and the incomplete "In country heaven". In October, Thomas sent a draft of the first 39 pages of 'The Town That Was Mad' to the BBC. The task of seeing this work through to production as Under Milk Wood was assigned to the BBC's Douglas Cleverdon, who had been responsible for casting Thomas in 'Paradise Lost'.
By the time of the 2023 election, Peña was considered a conservative politician who opposes the legalization of abortion and same-sex marriage. In May 2017, however, he had stated that he was in favor of same-sex marriage, while saying in regards of abortion that he was open for it to "be discussed in a sincere environment and without prejudice". He reversed position shortly afterwards following criticism from conservative sectors. During his 2023 campaign, he promised to create 500,000 jobs. He also ruled out raising taxes. On foreign policy, Peña pledged to maintain Paraguay's diplomatic relations with the Republic of China (Taiwan). In May 2023, Peña announced that he intended to move the Paraguayan embassy in Israel from Tel Aviv to Jerusalem after being sworn in as president; a move that was previously made by Horacio Cartes in 2018, but reversed by Mario Abdo Benítez later that year. Peña eventually attended the inauguration of said embassy in December 2024. Peña and his government expressed vocal support for Israel during the Gaza war and the Twelve-Day War, with Paraguay siding with Israel during South Africa's genocide case against Israel. As president, Paraguay restored diplomatic relations with Venezuela in November 2023; relations were strained since 2019. Relations between the two nations were broken again in February 2025, however, after Peña recognized Edmundo González as the winner of the 2024 Venezuelan presidential election. On the 2026 United States intervention in Venezuela, Peña stated that "it can only bring good news".
In the Buddhist Abhidharma traditions like the Theravāda, more systematized explanations of the twelve nidanas developed. As an expository device, the commentarial traditions of the Theravāda, sarvāstivāda-vaibhasika and sautrantika schools defended an interpretation which saw the 12 factors as a sequence that spanned three lives. This is sometimes referred to as the "prolonged" explanation of dependent origination. The three life interpretation can first be seen in the Paṭisambhidāmagga (I.275, circa 2nd or 3rd c. BCE). It is also defended by the Theravāda scholar Buddhaghosa (c. fifth century CE) in his influential Visuddhimagga (Vism.578–8I) and it became standard in Theravada. The three-lives model, with its "embryological" interpretation which links dependent origination with rebirth was also promoted by the Sarvāstivāda school as evidenced by the Abhidharmakosa (AKB.III.21–4) of Vasubandhu (fl. 4th to 5th century CE) and the Jñanaprasthana. Wayman notes that this model is also present in Asanga's Abhidharmasamuccaya and is commented on by Nagarjuna. The three lives interpretation can be broken down as follows:
2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by names such as Nexus or Erox, is a psychedelic drug of the phenethylamine and 2C families. The drug is used as a recreational drug and is usually taken orally. 2C-B produces hallucinogenic, mild stimulant, and mild entactogenic-like effects. Its hallucinogenic effects at typical doses are milder than those of other psychedelics like LSD or psilocybin. The drug acts as a potent partial agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. Numerous analogues and derivatives of 2C-B are known, such as DOB, 2C-B-FLY, and 25B-NBOMe among others. 2C-B was developed by Alexander Shulgin in 1974 and was described by him in the scientific literature in 1975. The drug emerged as a novel recreational designer drug and MDMA (ecstasy) substitute in the mid-1980s. Subsequently, it became a controlled substance in the United States in the mid-1990s. 2C-B was one of the first 2C psychedelics to be described. It is the most popular and well-known of the 2C psychedelics and is one of the most widely used designer drugs.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It consists of nicotinamide, ribose, and phosphate groups.
No. NMN is a precursor, while NAD+ is the dinucleotide product formed after an adenylate group is added. They are distinct molecules with different cellular roles.
Small amounts of NMN have been reported in several foods, including some vegetables and meats. The concentrations are variable and usually much lower than those used in laboratory research.
Liquid chromatography coupled with tandem mass spectrometry is widely used because it can separate NMN from related nucleotides and quantify low concentrations. Stable isotope-labeled internal standards help correct for matrix effects and recovery losses. Ultraviolet detection alone is less specific for complex biological matrices.